19-20 February, 2019 | San Diego, CA

Day One
Tuesday, January 30, 2018

Day Two
Wednesday, January 31, 2018

Chairs’ Opening Remarks

Applying Liquid Biopsy for the Advancement of Precision Medicine

The Whole Transcriptional Landscape of Circulating Tumor Cells Compared to Metastases in Stage IV Breast Cancer


  • Better understanding of CTC-biology compared to metastasis may shed light on treatment opportunities and help advance the application of CTCs as liquid biopsies in clinical practice
  • Demonstrating the feasibility of gene expression profiling of rare CTCs
  • Evaluating whether whole transcriptome sequencing (RNA Seq) gene expression profiling of ANGLE Parsortix isolated CTCs may serve as a surrogate for biopsies of macro metastases

The Liquid Biopsy State of Play: From Prognostic to Predictive


  • Where do we currently stand with the clinical impact of liquid biopsy on the delivery of personalized care?
  • Analyzing the application of liquid biopsy for longitudinal disease monitoring to inform resistance, treatment selection and disease recurrence
  • Discussing the evolution of liquid biopsy testing towards a future of early detection and screening of prodromal populations
  • How far have we come, and what do we need to do, in order to continue the integration of liquid biopsies into the precision medicine paradigm?

Harnessing Liquid Biopsy Testing for Precision Medicine Patient Selection


  • Utilizing circulating biomarkers as clinical research tools to produce novel predictive biomarker signatures
  • Understanding how liquid biopsies can add another dimension to the robust selection of patient responders for targeted therapeutics
  • Discussing the route for bridging liquid biopsy patient selection assays to IDEs for pivotal clinical studies

Session Q&A


  • Q&A with the sessions speakers
  • Beyond NSCLC, where are we seeing benefit from the us of liquid biopsy and how do we advance the clinical utility of testing in such indications?
  • Despite all the investment and innovation in precision medicine we are still prognostic in our use, how do we get to a place where we are getting predictive utility?
  • What will the precision medicine field look like over the next 5-10 years with the fast developing applications of liquid biopsies?

Speed Networking & Morning Refreshments

Evaluating the Scope of Clinical Utility for Circulating Biomarkers

Analyzing the Clinical Impact of ctDNA Based Testing


  •  Dissecting clinical utility: Is there a limit on how impactful a clinical decision can be made from ctDNA based testing?
  • Validating the impact of ctDNA testing on the accuracy of clinical decision: What’s real, what’s technical, what’s just tumor heterogeneity?

Multigene Blood mRNA Signatures for Diagnosis and Therapeutic Monitoring of Myeloma, Melanoma, Colon, Prostate, Neuroendocrine Gut and Lung tumors


  • Blood Transcript analysis demonstrates high sensitivity and specificity as a diagnostic tool
  • Stratifies patients into stable and progressive disease groups
  • Functions as a complementary diagnostic/ predictor signature for the efficacy of a specific drug or isotope therapy
  • Monitors treatment efficacy and identifies the risk of disease progression and treatment failure
  • Confirms complete resection and identifies minimum residual disease post-therapy or surgery

Evaluating the Evolving Use of Circulating Tumor Cells for Liquid Biopsy


  • Addressing phenotypic heterogeneity of CTCs and their effectiveness for prognostic clinical monitoring
  • Evolving sampling detection of circulating tumor cells to improve sensitivity of testing

Lunch & Networking

The Clinical Application of CXCR4 Expression on Tumor and Circulating Tumor Cells as a Potential Prognostic and Predictive Response Marker in Extensive-Disease Small Cell Lung Cancer


  • Exploratory analyses evaluated CXCR4 expression on available baseline tumor tissue and on circulating tumor cells (CTCs) collected at baseline in patients with extensive disease small cell lung cancer (ED-SCLC).
  • Patients with ED-SCLC were treated with either standard of care etoposide/carboplatin (CE) or CE+LY2510924.
  • Baseline CXCR4 expression in tumor tissue and on CTCs was explored for the potential to be prognostic of survival or predictive of LY2510924 treatment response

Getting Closer to the Site of Action: Extracellular Vesicles as Biomarkers for Cancer Immunotherapy Drug Development


  • Evaluating the scope for the clinical applicability of extracellular vesicles as circulating biomarkers
  • Building the methodology and technical expertise for fluid based extracellular vesicle testing

Exploiting Extracellular Body Fluid RNA for Precision Medicine Purposes


  • Discussing various workflows for RNA sequencing of body fluid derived RNA, including probe based target capture as a sensitive RNA sequencing workflow to study thousands of mRNA and lncRNA genes in cell-free RNA from cancer patients’ plasma and urine
  • Debating the pre-analytical jungle of RNA targeted liquid biopsies and need for standardization, as part of the ongoing exRNAQC study

Session Q&A


  • Q&A with the sessions speakers
  • Where does the most clinical value lie for liquid biopsies?
  • Evaluating the pros and cons of circulating biomarkers and their attribution across disease indications

Afternoon Refreshments

Standardization and Validation: The Challenges Associated with Establishing Accuracy of Liquid Biopsy Assays

Improving Sensitivity and Accuracy While Reducing Cost: HRM Enables Rapid Mutation Assessment Prior to Targeted Re-Sequencing


  • Discussing novel forms of real time PCR that reduce the effort for sample preparation while also providing rapid assessment of mutation status prior to targeted resequencing
  • Discussing implementation of mutation enrichment via COLD-PCR or NaME-PrO together with high resolution melting
  • Highly sensitive detection of micro-satellite instability in plasma as a unique application
  • Application in circulating DNA from clinical cancer samples will be presented

Product Development Updates for Liquid Biopsy Reference Standards


  • Additional information to follow

Super Selective Primers for Multiplex Real-time PCR Assays that Assess the Abundance of Rare Mutations Associated with Cancer


  • “SuperSelective” PCR primers, due to their unique design, are extraordinarily specific, able to selectively initiate the synthesis of amplicons on ten mutant DNA fragments in the presence of 1,000,000 wild-type DNA fragments
  • Sets of SuperSelective primers, each possessing unique 5’-tag sequences, enable the amplicons generated from each mutant to be distinguished by differently colored molecular beacon probes
  • Inclusion of primers for a wild-type reference gene enables the abundance of each type of mutant DNA fragment to be assessed by determining the difference between its threshold value and the threshold value of the reference gene

Session Q&A


  • Q&A with the sessions speakers
  • In such a dynamic, multi-stakeholder industry, how can we work together to derive a level of standardization and validation across the field?
  • Debating the improvement in the sharing of data, particularly for LDTs, for test validation and standard comparison
  • Discussing the challenges of validation, the best materials and controls to use the and best approaches for robust validation
  • Developing standards for downstream bioinformatics: How do we or can we unify research, academic and commercial lab processes?
  • Discussing the lack of adequate reference materials (both positive and negative),what does one use as a “gold standard” reference method to compare against?
  • Standardizing terms: Aligning metrics and endpoints for analytical performance to truly assess assay capabilities
  • Debating trade-offs between assay technology and ultimately from a physician’s perspective, what is most important?

Chairs’ Closing Remarks

End of Day One